Open Innovation to Improve Healthcare

Transcription

1 Insérer le visuel thématique Open Innovation to Improve Creating new pharmaceutical treatments through external relationships (or Who s building the puzzle?)

2 Insérer visuel thématique New Pharmaceutical Treatments Are The Sum of Widely Divergent Parts Fundamental Premise: (1) New pharmaceutical treatments that are (2) safe and effective, and (3) available to patients = Improved 2

3 Can Any One Company Have the Best Solutions Across Those Parts? How do we get there? Requires vision and expertise concerning: Disease states; Target Identification Chemical or Biologic Therapeutic Agent discovery, application and formulation Patient populations; Clinical trials Delivering it to the patient, i.e., manufacturing, distributing, marketing, pricing 3

4 Open Innovation Has Been a Part of the Pharmaceutical Industry Working with doctors, universities, research institutions Partnering with governments/institutions concerning neglected populations or orphan diseases Malaria Sleeping sickness 4

5 Large Pharma Already Has Used Open Innovation to Save Lives 5

6 External BD is Now Part of Internal R&D from Internal Dreams to World Dreams Patient focus expands Externally Global now means Local Focus 6

7 USA BIOTECH AgaMatrix, Salem, NH, USA Alopexx, Cambridge, MA, USA CureDM, Wilmington, DE, USA Dyax, Cambridge, MA, USA Exelixis, San Francisco, CA, USA ImmunoGen, Cambridge, MA, USA Merrimack, Cambridge, MA, USA Micromet, Bethesda, MD, USA Regeneron, Tarrytown, NY, USA Syntiron, St Paul, MN, USA Wellstat, Gaithersburg, MA, USA ACADEMIA California Institute of Technology, Pasadena, CA, USA John Hopkins University, Baltimore, MD, USA MIT Center for Biomedical Innovation (CBI), USA Rockefeller University, New-York, NY, USA Salk Institute for Biological Studies, La Jolla, CA, USA University of Pennsylvania, Philadelphia, PA, USA Large Pharma Invests In Global Science To Provide New Medicines EUROPE BIOTECH Genfit, Lille, France Novozymes, Bagsvaerd, Denmark Oxford BioMedica, Oxford, UK ZealandPharma, Glostup, Denmark ACADEMIA/CONSORTIA AVIESAN (French Life Sciences and Alliance) The Charité University, Berlin, Germany Innovative Medicines Initiative (IMI) European Public Private Partnerships Institut de la Vision, Paris, France ACQUISITION Fovea, Paris, France ASIA BIOTECH BioWa, Japan Glenmark, Mumbai, India Kitasato Institute Research Center for Biologicals, Japan Kyowa Kirin, Japan ACADEMIA Institute of Hematology and Blood diseases, Tianjin, China Khotro/Khidi, Korea SIBS, China BiParSciences, CA, USA ACQUISITION ACQUISITION Shantha Biotechnics, Hyderabad, India 7

8 Investing And Partnering To Be Openly Innovative In China 8

9 Large Pharma Partnerships Create Efficiencies and Seed New Industries C. Viehbacher raises possibility to open BioLaunch to other companies in need of bioproduction, notably French small and mediumsized companies. Strong Public Authority interest in the development of the biotechnology field in France. 9 Interest of SA to be part of the development of biotech in France and benefit from additional opportunities in order to optimize its manufacturing capacities.

10 Open Innovation Is Not Inconsistent With IP Ownership Puzzle Pieces That are Owned (patented; trade secret) Can Be Sold Licensed Supplied Taught For a Particular disease Particular region Particular user At a particular cost (or at no cost) depending on the situation 10

11 Conclusion: Pharma Has Opens Arms to Open Innovation From Basic Research to Patient and disease identification to Manufacturing and distribution Large Pharma is working with others to bring new medicines to a world that needs them 11